145 related articles for article (PubMed ID: 38639818)
1. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
Gibiansky L; Ng CM; Gibiansky E
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38639818
[TBL] [Abstract][Full Text] [Related]
2. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
3. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
4. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
5. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
[TBL] [Abstract][Full Text] [Related]
6. Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):23-34. PubMed ID: 28918570
[TBL] [Abstract][Full Text] [Related]
7. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):17-26. PubMed ID: 28074395
[TBL] [Abstract][Full Text] [Related]
8. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
[TBL] [Abstract][Full Text] [Related]
9. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations.
Byun JH; Jeon HS; Yun HY; Kim JK
PLoS Comput Biol; 2024 Apr; 20(4):e1012066. PubMed ID: 38656966
[TBL] [Abstract][Full Text] [Related]
10. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
Yan X; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):141-6. PubMed ID: 22215144
[TBL] [Abstract][Full Text] [Related]
11. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
12. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
Yan X; Ruixo JJP; Krzyzanski W
AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
[TBL] [Abstract][Full Text] [Related]
13. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
Eudy RJ; Riggs MM; Gastonguay MR
AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
[TBL] [Abstract][Full Text] [Related]
14. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
15. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
16. Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model.
Ternant D; Le Tilly O; Picon L; Moussata D; Passot C; Bejan-Angoulvant T; Desvignes C; Mulleman D; Goupille P; Paintaud G
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834236
[TBL] [Abstract][Full Text] [Related]
17. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
18. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of target-mediated drug disposition.
Peletier LA; Gabrielsson J
Eur J Pharm Sci; 2009 Dec; 38(5):445-64. PubMed ID: 19786099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
